# Suzhou Medilink Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/suzhou-medilink-therapeutics

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.medilinkthera.com
- Total disclosed funding: $120M
- Latest round: Series B (Mar 14, 2022)
- Investors on record: 6

## About

Founded in 2020 and based in Suzhou, China, Medilink Therapeutics has focused its efforts on ADC development. In March 2022, Suzhou Medilink Therapeutics Ltd. raised USD 70 million in series B funding from Lyfe Capital , Qiming Venture Partners, Loyal Valley Capital, HighLight Capital and Legend Capital. Medilink develops ADC candidates based on its TMALIN® platform, designed for high drug-antibody ratio, stability, and tumor microenvironment activation. Its key drug candidates include: L201, targeting B7-H3, granted FDA Breakthrough Therapy designation (June 2025) and currently in Phase III for small cell lung cancer (SCLC) and nasopharyngeal cancer; YL211, a c-MET targeting ADC under global license to Roche for solid tumors, with Roche leading global development following IND initiation in 2024; YL217 (CDH17 ADC, IND accepted May 2025) and YL242 (VEGF ADC, FDA/CDE accepted) are advancing toward clinical stages. Medilink also engages in licensing and collaboration services with global pharma partners, leveraging its platform strengths. The company generates revenue from milestone and licensing payments under collaboration agreements (with Roche, Zai Lab, BioNTech), and anticipates future royalty income tied to ADC commercialization. Additional sources include research service fees and platform licensing.

## Funding rounds

- Series B, Mar 14, 2022, $70M — Legend Capital, Qiming Venture Partners, HighLight Capital, LYFE Capital, Loyal Valley Capital
- Series A, Mar 1, 2021, $50M — Qiming Venture Partners, Loyal Valley Capital, Apricot Capital

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series A, Series B
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series A
- Legend Capital — Series B
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- LYFE Capital — Series B